New Frontiers for Neuromuscular Blockade Use and Reversal: Addressing Challenges for Improved Clinical and Economic Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN

New Frontiers for Neuromuscular Blockade Use and Reversal: Addressing Challenges for Improved Clinical and Economic Outcomes is a two-part webinar series focusing on the latest developments in the use and reversal of neuromuscular blockade

These are archives of live webinars held between August 10 and August 12, 2020.

If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all three or in order.

These activities are valid from August 15, 2020 to August 15, 2022


This series is supported by an educational grant from Merck Sharp & Dohme Corp.


 
Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Neuromuscular blocking agents (NMBAs) are used in many surgical procedures and have enabled new surgical advances. The expanded landscape of NMB reversal drugs allows for fast and complete neuromuscular blockade (NMB) reversal and the reduction of postoperative complications from residual block. In the United States, neostigmine/glycopyrrolate and sugammadex are the primary agents for pharmacologic antagonism of NMBAs. While neostigmine and an anticholinergic have been available for decades, sugammadex has only recently become available. This webinar will take a close look at these options and what managed care needs to know about NMB and reversal in a variety of surgeries and clinical settings in which the use of NMB reversal agents played a significant role in the patients' clinical outcome.


New Frontiers for Neuromuscular Blockade Use and Reversal: Addressing Challenges for Improved Clinical and Economic Outcomes

  1. Explain the science of neuromuscular blockade (NMB) and reversal
  2. Explore current barriers to preventing residual paralysis in the perioperative setting
  3. Compare and contrast newer options for neuromuscular blockade reversal for preventing residual paralysis with regard to efficacy, safety, and pharmacoeconomics
  4. Analyze strategies used in monitoring and reversing anesthetic medications and preventing adverse drug events
  5. Integrate strategies for prevention of rNMB into care for patients in the perioperative setting
       Physician, Nursing and CMCN credits valid to August 15, 2022

New Frontiers for Neuromuscular Blockade Use and Reversal: Managed Care Considerations in an Evolving Paradigm

  1. Explain the physiology, incidence, and complications of residual neuromuscular blockade (NMB)
  2. Compare the options for neuromuscular blockade reversal and monitoring with regard to efficacy, safety, and pharmacoeconomics
  3. Consider patient and procedural risk factors when managing reversal of neuromuscular blockade
  4. Analyze recent clinical data on agents available for neuromuscular blockade reversal
  5. Assess managed care considerations of NMB reversal agents and the role that payers can play in this paradigm
       Physician, Nursing and CMCN credits valid to August 15, 2022